Kathryn Kinch, senior pharma product manager at GlobalData, said, “Increased approvals of biosimilars are likely to lower biologic prices, enhancing consumer demand and competition among drug ...

For instance, 90% of all medicines prescribed in the U.S. are not branded drugs. They are generics and biosimilars. The vast majority of generic medicines in the U.S. cost $20 or less; average ...

Editor’s note: “Behind the News“ is the product of Sun staff assisted by the Sun’s AI lab, which includes a variety of tools such as Anthropic’s Claude, Perplexity AI, Google Gemini and ...

Of the 50 different drugs approved by the U.S. Food and Drug Administration (FDA) in 2024, 18 of these agents were biosimilars, eight of which target reference products with no previous biosimilar ...

this year’s Biosimilars USA conference promises to explore the developments in biosimilar drug development During a speech given this week in Washington, DC, FDA Commissioner Scott Gottlieb ...

Biosimilars are near-copies of complex biologic drugs grown in cells, that have been analysed and tested in trials showing that they have the same safety and efficacy profile as the originator drug.

Fresenius Kabi also makes biosimilars, the generic forms of expensive biologic drugs such as Humira and Stelara. The United States is typically the last developed country where biosimilars appear on ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

led by strong demand for its generics and biosimilar drugs in its key U.S. and European markets. Healthcare & Pharmaceuticalscategory· May 5, 2025 Trump signals an announcement on medicine costs ...

Gantt charts are indispensable tools in project management, providing a visual representation of a project's schedule. They allow you to track task progress, understand task relationships ...

The next phase of growth once Revlimid sales taper after the drug goes off patent in January 2026, will be driven by biosimilars and Semaglutide portfolios. The company is likely to post double-digit ...

South Korea’s two leading drugmakers, Celltrion Inc. and Samsung Bioepis Co., have achieved a significant milestone in the European biosimilar market, capturing over 50% market share in the six ...